Form 4 for BAX Baxter International
Accepted 2023-06-05 00:00:00 ET · period of report 2023-06-01 · accession 0001062993-23-012907 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-05 | 2023-06-01 | BAX | Toth Christopher A. | EVP, Group Pres, Kidney Care | A - Grant | $0.00 | +106.4K | 106.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $1 par value | 2023-06-01 | A | A | 106,358 | $0.00 | 106,358 | D | — | — | (F1) Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co. |